Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S

Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Christina Law

 

2

Reason for the notification

 

a)

Position/status

Member of the Board of Directors

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

ADRs

 

 

Identification code

NVO

 

b)

Nature of the transaction

Purchase of ADRs

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

 

DKK 349.06

952 ADRs

 

 

 

DKK 349.04

598 ADRs

 

 

 

 

 

DKK 349.03

800 ADRs

 

 

d)

Aggregated information

2,350 ADRs
DKK 820,252.49

 

e)

Date of the transaction

2025-08-18

 

f)

Place of the transaction

New York Stock Exchange

 

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Attachment